FDA Allows Early Access To Experimental Pancreatic Cancer Drug

FDA Allows Early Access To Experimental Pancreatic Cancer Drug In clinical trials, daraxonrasib has been shown to double the average survival time for patients who had received conventional treatments, HealthDay reports. Other pharmaceutical news is about IBD therapy, GLP-1s, "skinny labels," and more. https://kffhealthnews.org/morning-breakout/pharma-and-tech-main-hed-should-mention-early-access/